BREAST CANCER
![Foto de BREAST CANCER](/img/grupo.png)
![Foto de Hospital Clínico Universitario Lozano Blesa](/img/noimage_org.png)
Hospital Clínico Universitario Lozano Blesa
Zaragoza, EspañaPublications in collaboration with researchers from Hospital Clínico Universitario Lozano Blesa (12)
2023
-
Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry
Breast Cancer Research and Treatment, Vol. 201, Núm. 2, pp. 151-159
-
Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme
European Journal of Cancer, Vol. 182, pp. 3-14
2021
-
One-step nucleic acid amplification (Osna) of sentinel lymph node in early-stage endometrial cancer: Spanish multicenter study (endo-osna)
Cancers, Vol. 13, Núm. 17
-
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL
Annals of Oncology, Vol. 32, Núm. 4, pp. 488-499
2019
-
Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry)
Scientific Reports, Vol. 9, Núm. 1
2016
-
Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile
Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428
2013
2011
-
Evidence for a link between TNFRSF11A and risk of breast cancer
Breast Cancer Research and Treatment, Vol. 129, Núm. 3, pp. 947-954
-
Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer
PLoS Biology, Vol. 9, Núm. 11
2010
-
SEOM clinical guidelines for the treatment of metastatic breast cancer
Clinical and Translational Oncology, Vol. 12, Núm. 11, pp. 719-723
2008
-
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer
Journal of the National Cancer Institute, Vol. 100, Núm. 11, pp. 805-814